Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Trump considers tax hike on Americans making $2.5...
GOP senators: Congress should vote on Trump’s potential...
White House highlights over $2B in savings from...
GOP talk on millionaire tax hike ‘makes no...
Trump’s first vice president urges his old boss...
Department of Justice opens criminal investigation into NY...
Trump claims ‘I don’t know her’ and ‘listened...
Rubio just got an additional job in Trump’s...
OpenAI’s Sam Altman thanks Sen John Fetterman for...
Former Supreme Court Justice David Souter dead at...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Investing

Significant Progress with B7-H3 Targeting Radio-Antibody (BetaBart)

by admin October 4, 2024
October 4, 2024
Significant Progress with B7-H3 Targeting Radio-Antibody (BetaBart)

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce regulatory and manufacturing progress for its B7-H3 targeting radio-antibody, BetaBart.

Pre-IND meeting request with FDA submittedFirst GMP batch of antibody + chelator successfully produced

The monoclonal antibody is the first radiopharmaceutical therapeutic agent developed by Radiopharm Ventures, the Joint Venture formed between Radiopharm Theranostics (RAD) and MD Anderson Cancer Center (MDACC).

The strong preclinical data package combined with GMP quality production, supported the pre-IND submission to the US Food and Drug Administration (FDA). Preparations are on track to prepare the IND submission with the FDA and subsequently start the Phase I/II First-In-Human (FIH) therapeutic trial with BetaBart in multiple tumour types in the US, expected for mid-2025.

B7-H3 is an immune checkpoint molecule that is overexpressed in several tumour types, and represents a highly attractive target for antibody-based cancer immunotherapy. Deregulated B7-H3 expression is linked with tumour aggressiveness and poor outcomes. BetaBart is the first and only targeted radiopharmaceutical in development against the 4Ig subtype of B7-H3, which is the most common subtype expressed on human tumours.

Multiple preclinical studies with BetaBart show tumour shrinkage and prolonged survival in animals treated with this radiotherapeutic agent. The monoclonal antibody, invented at MDACC, has been specifically engineered with a shorter blood circulation time and reduced affinity for on-target off- tissue toxicity, leading to a final molecule that is highly promising for human use in clinical settings.

BetaBart will be used in the planned FIH clinical trial as a 177 Lutetium-conjugated therapeutic. The supply chain of the isotope Lu177 has been secured by multiple contracts.

Radiopharm’s Managing Director and CEO Riccardo Canevari said: ‘We are extremely pleased with the strong collaboration with MD Anderson and the early results we saw with BetaBart (RV-01) are impressive, so we’re looking forward to developing this further.’

Dr David Piwnica-Worms of the MDACC Department of Cancer Systems Imaging said: ‘It has been an exciting and rewarding journey for our research team to be working with our strong partners at RAD to bring this antibody through the regulatory steps required for human testing.’

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world’s leading universities and institutes. The pipeline has been built based on the potential to be first-to-market or best-in-class. Learn more at Radiopharmtheranostics.com.

Click here for the full ASX Release

This post appeared first on investingnews.com

previous post
Energy Fuels: Uranium Sector Strong, Now Ramping Up Rare Earths
next post
Troy Minerals Completes Infill Soil Sampling at Lac Jacques

You may also like

Astral’s Group Gold Mineral Resource Increases to 1.46Moz...

November 3, 2024

Oil Markets Buckle Under Tariff Pressure, Recession Fears...

April 9, 2025

Zinc Price 2024 Year-End Review

January 14, 2025

5 US Longevity and Anti-aging Stocks to Watch...

September 5, 2024

Anteros Metals: Science-based, Diversified Mineral Exploration in Eastern...

February 4, 2025

Black Swans, White Swans and Trump’s Clash with...

December 10, 2024

5 Experts Share Highest-Conviction Sectors for 2025

January 4, 2025

World Copper Announces Grade-Confirmation Programme at the Zonia...

August 12, 2024

Latest Drilling Confirms Deeper Mineralised Trends at Lo...

September 19, 2024

Uranium Price 2024 Year-End Review

December 17, 2024

Recent Posts

  • Trump considers tax hike on Americans making $2.5 million or more per year
  • GOP senators: Congress should vote on Trump’s potential Iran nuclear deal
  • White House highlights over $2B in savings from DEI cuts during Trump administration’s first 100 days
  • GOP talk on millionaire tax hike ‘makes no sense,’ Trump White House alum says
  • Trump’s first vice president urges his old boss against raising taxes on wealthy Americans

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (712)
    • Investing (2,058)
    • Politics (2,553)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.